Pharma and life sciences cases are among the highest-stakes scenarios in consulting interviews. Unlike general healthcare cases that focus on hospitals or payers, these cases center on drug development pipelines, regulatory approval pathways, and commercialization strategy — a domain where a single pricing decision can shift billions in revenue.
What Makes Pharma & Life Sciences Cases Different
Three structural features separate pharma cases from standard strategy problems:
| Feature | Standard Strategy Case | Pharma & Life Sciences Case |
|---|---|---|
| Time horizon | 1–3 years | 7–15 years (R&D to patent expiry) |
| Revenue model | Volume x Price | Payer mix x Reimbursement x Adherence |
| Key risk | Competitive entry | Regulatory failure or patent cliff |
| Stakeholders | Customer, competitor | FDA/EMA, physicians, payers, patients |
In our experience working with candidates preparing for McKinsey, BCG, and Bain interviews, pharma cases appear in roughly 10–15% of case rounds — and that share is growing as healthcare consulting practices expand.
The Four Sub-Sectors You Must Know
Pharma and life sciences is not a single industry. Each sub-sector has distinct economics, and your case structure must reflect which one you are analyzing.
mindmap
root((Pharma & Life Sciences))
Pharmaceuticals
Branded drugs
Generics
Biosimilars
Biotechnology
Biologics
Cell & gene therapy
Diagnostics
Medical Devices
Implantables
Surgical instruments
Digital health
Contract Services
CROs
CDMOs
Real-world evidence
Pharmaceuticals drive the largest share of consulting engagements. Cases typically involve product launch timing, pricing strategy across markets, or portfolio rationalization after an M&A. Margins range from 15–25% for generics to 60–80% for branded specialty drugs.
Biotechnology cases focus on commercialization strategy for novel therapies. Based on our analysis of consulting case libraries, biotech scenarios often test your ability to evaluate clinical trial data and translate it into a go/no-go investment recommendation.
Medical Devices follow a different economic model — shorter development cycles (3–7 years vs. 10–15 for drugs), physician-driven purchasing decisions, and recurring revenue from consumables or service contracts.
Contract Services (CROs and CDMOs) are a growing case category. These B2B businesses require capacity planning, client concentration analysis, and growth strategy frameworks.
A Five-Step Framework for Pharma Cases
When you receive a pharma or life sciences case, apply this structured approach:
flowchart TD
A[Identify Sub-Sector] --> B[Map the Value Chain Stage]
B --> C[Assess Regulatory & IP Landscape]
C --> D[Quantify Commercial Opportunity]
D --> E[Evaluate Strategic Options]
B -->|R&D| B1[Pipeline analysis, clinical trial phases]
B -->|Launch| B2[Market access, KOL engagement]
B -->|Mature| B3[Life-cycle management, patent defense]
C -->|Key Question| C1[What approvals are needed? What IP protection exists?]
D -->|Key Question| D1[Patient population x Penetration x Price x Duration]
E -->|Key Question| E1[Build vs. license vs. acquire?]
Step 1: Identify the Sub-Sector
Within the first 30 seconds, clarify whether the case involves pharmaceuticals, biotech, medical devices, or services. The economics differ so fundamentally that a generic “healthcare framework” will miss critical drivers.
Step 2: Map the Value Chain Stage
Pharma cases span three lifecycle stages — R&D, launch, and mature product management. A market entry case for a Phase III drug requires pipeline risk analysis, while the same question for a 10-year-old blockbuster centers on patent cliff defense and biosimilar competition.
Step 3: Assess Regulatory and IP Landscape
Every pharma case has a regulatory dimension. At minimum, ask: What approval pathway applies? What is the remaining patent life? Are there exclusivity provisions (orphan drug, pediatric extension)?
Step 4: Quantify the Commercial Opportunity
The standard revenue formula for pharma is:
Revenue = Eligible Patients x Diagnosis Rate x Treatment Rate x Market Share x Price per Course x Duration
This differs from the typical Volume x Price equation because patient identification and adherence are major variables. In our experience, candidates who break out each multiplier score higher than those who estimate a lump-sum market size.
Step 5: Evaluate Strategic Options
Pharma strategy decisions typically fall into three categories: build (internal R&D), license (in-licensing or partnership), or acquire (M&A). Each has different risk/return profiles and timeline implications. For M&A-heavy cases, pair this with the M&A case framework.
Common Pharma Case Archetypes
Based on our analysis of 800+ consulting interview cases, pharma and life sciences scenarios cluster into five patterns:
| Archetype | Typical Prompt | Key Analysis |
|---|---|---|
| Drug Launch | “Should we launch Drug X in Europe?” | Market access, pricing, competitive timing |
| Portfolio Prioritization | “Which 3 of 8 pipeline assets should we fund?” | NPV analysis, probability of success, strategic fit |
| Patent Cliff | “Revenue drops 40% in 2 years — what now?” | Life-cycle management, biosimilar defense, diversification |
| Biotech Acquisition | “Should we acquire this biotech for $2B?” | Pipeline valuation, synergies, regulatory risk |
| Pricing & Access | “Set the price for a rare disease therapy” | Willingness to pay, health technology assessment, reference pricing |
Specialized Firms to Know
Beyond the MBB firms, several specialist consultancies dominate pharma and life sciences. Knowing these firms signals industry awareness during interviews:
- ZS Associates — commercial strategy, sales force effectiveness
- IQVIA — data-driven analytics, real-world evidence
- Putnam Associates — pricing and market access
- Clearview Healthcare Partners — strategy for biopharma
- Health Advances — commercial due diligence
These firms recruit candidates with strong quantitative skills and, in many cases, scientific backgrounds (PhDs, MDs, PharmDs).
Key Takeaways
- Pharma and life sciences cases require sub-sector identification in the first 30 seconds — pharmaceuticals, biotech, medical devices, and contract services each have distinct economics
- The revenue formula (Patients x Diagnosis Rate x Treatment Rate x Share x Price x Duration) replaces the standard Volume x Price equation
- Every case has a regulatory and IP dimension — always ask about approval status and patent life
- The five-step framework (Sub-Sector → Value Chain Stage → Regulatory/IP → Commercial Sizing → Strategic Options) provides structure without being rigid
- Drug launch and portfolio prioritization are the two most common case archetypes, appearing in approximately 60% of pharma consulting interviews
Ready to practice? Explore healthcare industry cases in our case library, or test your pharma case skills with an AI Mock Interview.